JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Home・Aktien・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Geschlossen

3.8 -5.94

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.79

Max

3.88

Schlüsselkennzahlen
By Trading Economics
Einkommen	466K -27M
Verkäufe	2M 15M
Gewinnspanne	-178.834
Angestellte	141
EBITDA	-2M -29M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+287.07% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	4. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	24M 252M
Vorheriger Eröffnungskurs	9.74
Vorheriger Schlusskurs	3.8

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

3.17 / 3.4644 Unterstützung & Widerstand

Voyager Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Apr. 2026, 19:19 UTC

Akquisitionen, Fusionen, Übernahmen

Intertek Group Rejects EQT's Revised Offer

24. Apr. 2026, 23:37 UTC

Akquisitionen, Fusionen, Übernahmen

Scoring the Cook Era -- Barrons.com

24. Apr. 2026, 20:51 UTC

Akquisitionen, Fusionen, Übernahmen

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. Apr. 2026, 20:50 UTC

Market Talk

Wichtige Nachrichtenereignisse

Financial Services Roundup: Market Talk

24. Apr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24. Apr. 2026, 20:39 UTC

Akquisitionen, Fusionen, Übernahmen

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. Apr. 2026, 20:09 UTC

Ergebnisse

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24. Apr. 2026, 19:48 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24. Apr. 2026, 19:25 UTC

Akquisitionen, Fusionen, Übernahmen

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. Apr. 2026, 19:25 UTC

Akquisitionen, Fusionen, Übernahmen

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24. Apr. 2026, 19:22 UTC

Ergebnisse

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24. Apr. 2026, 19:06 UTC

Ergebnisse

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24. Apr. 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24. Apr. 2026, 18:30 UTC

Akquisitionen, Fusionen, Übernahmen

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24. Apr. 2026, 18:28 UTC

Akquisitionen, Fusionen, Übernahmen

Intertek Rejects Revised EQT Offer

24. Apr. 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24. Apr. 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24. Apr. 2026, 17:42 UTC

Ergebnisse

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24. Apr. 2026, 17:28 UTC

Ergebnisse

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24. Apr. 2026, 17:28 UTC

Market Talk

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24. Apr. 2026, 17:12 UTC

Market Talk

Global Equities Roundup: Market Talk

24. Apr. 2026, 17:11 UTC

Market Talk

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24. Apr. 2026, 17:09 UTC

Market Talk

Ergebnisse

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24. Apr. 2026, 17:09 UTC

Akquisitionen, Fusionen, Übernahmen

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. Apr. 2026, 17:06 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24. Apr. 2026, 16:51 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24. Apr. 2026, 16:20 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

24. Apr. 2026, 16:20 UTC

Market Talk

Wichtige Nachrichtenereignisse

Financial Services Roundup: Market Talk

24. Apr. 2026, 16:20 UTC

Market Talk

Ergebnisse

Auto & Transport Roundup: Market Talk

24. Apr. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Voyager Therapeutics Inc Prognose

Kursziel

By TipRanks

287.07% Vorteil

12-Monats-Prognose

Durchschnitt 14.67 USD 287.07%

Hoch 25 USD

Tief 8 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Voyager Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

Buy

Halten

Sell

Basierend auf 8 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Voyager Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

3.17 / 3.4644Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.